Anti-Ageing Drug Combo Extends Mouse Lifespan By 30%, Sparks Hope For Human Longevity
Quick Read
Summary is AI generated, newsroom reviewed.
A study reveals rapamycin and trametinib can extend mouse lifespan by 30%.
Treated mice showed improved health markers, including reduced inflammation.
Combined drugs resulted in a greater lifespan increase than either alone.
A groundbreaking study by the Max Planck Institute for Biology of Ageing in Germany has revealed that a combination of two FDA-approved drugs-rapamycin and trametinib-can extend the lifespan of mice by up to 30%. Beyond merely prolonging life, the treated mice exhibited improved health markers, including reduced inflammation, delayed tumor progression, and enhanced physical function.
Rapamycin, commonly used to prevent organ rejection, and trametinib, a cancer treatment, target different cellular pathways involved in aging. Their combined effect resulted in a more significant lifespan extension than either drug alone. While rapamycin alone extended lifespan by 17-18% and trametinib by 7-16%, their combination achieved a remarkable 26-35% increase.
As per a news release, although rapamycin and trametinib act on the same network, the combination achieves novel effects that are probably not solely due to an increase in dose. An analysis of gene expression in various tissues shows that the combination of the drugs influences the activity of the genes differently than is achieved by administering the drugs individually. There are specific changes in gene activity that are only caused by the combination of the two drugs.
The researchers plan to determine the optimal dose and route of administration of Trametinib to maximise the health and life-prolonging effects while minimising unwanted side effects. As Trametinib is already approved for human use, it is possible to test it in clinical trials.
"Trametinib, especially in combination with rapamycin, is a good candidate to be tested in clinical trials as a geroprotector. We hope that our results will be taken up by others and tested in humans. Our focus is on optimising the use of trametinib in animal models," explains Sebastian Gronke.
Co-senior author Professor Dame Linda Partridge (UCL Institute of Healthy Ageing and Max Planck Institute for Biology of Ageing) said, "While we do not expect a similar extension to human lifespans as we found in mice, we hope that the drugs we're investigating could help people to stay healthy and disease-free for longer late in life. Further research in humans in years to come will help us to elucidate how these drugs may be useful to people and who might be able to benefit."
These findings suggest potential for developing anti-aging therapies in humans. However, researchers caution that further studies and clinical trials are necessary to determine safety and efficacy in humans.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Entrepreneur finds alternative to make areca plates safer after US ban
Mangaluru: Entrepreneur and researcher Nivedan Nempe has developed an innovative, eco-friendly alternative following the recent US ban on arecanut leaf sheath dinnerware. His intervention comes at a crucial time, as areca growers and industry experts from Karnataka's areca belt have appealed to Prime Minister Narendra Modi to seek the lifting of the restriction. The US Food and Drug Administration (FDA) issued an import alert banning dinnerware made from areca catechu sheaths, citing the presence of naturally occurring toxins that may migrate into food at unsafe levels. The FDA's concerns significantly impacted India's $400-500 million areca plate industry, with nearly 80–85% of exports directed to the US. Most manufacturers are concentrated in Dakshina Kannada and Shivamogga, and the ban threatens the livelihoods of many families. Nivedan, founder of Areca Tea and operating in Udupi and Shivamogga, acknowledged the FDA's concerns and told TOI: "As a preventive step, the FDA banned imports. But this severely affects Indian manufacturers. The Indian industry made efforts, including writing to the FDA, but the industry is at risk." In response, Nempe engineered a food-grade, anti-microbial paper lining that acts as a barrier between the food and the areca plate, preventing toxin migration and fungal growth. "The material is certified, heat-resistant up to 300°C, durable, printable, and gives a premium finish. It meets international safety standards without altering the existing production process," he said. While the innovation may increase production costs by 10–15%, Nivedan believes that it is the best way forward. "Our lab results were positive on all parameters. It even looks better than bagasse plates. My goal is to safeguard the industry and support the farmers by supplying this new food-grade paper."
&w=3840&q=100)
First Post
8 hours ago
- First Post
US okays Moderna's 'next generation' Covid-19 vaccine
The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target read more Moderna logo is seen displayed in this illustration taken, May 3, 2022. REUTERS Moderna, a vaccine manufacturer, said late last week that the FDA has authorised its next-generation COVID-19 vaccine. The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It's made in a way that allows for a lower dose, a fifth of the dose of its current COVID-19 vaccine, Spikevax (mRNA-1273) by refining its immune target. Moderna's approval was based on a phase 3 randomised controlled trial involving 11,400 participants ages 12 and older. The trial found that a 10-microgram (μg) dose of mNexspike demonstrated a 9.3% higher relative vaccine efficacy (rVE) compared to a 50-μg dose of Spikevax, with a 13.5% higher rVE in adults ages 65 and older. The two vaccinations have identical safety profiles, according to the manufacturer. STORY CONTINUES BELOW THIS AD The approval 'adds an important new tool to help protect people at high risk of severe disease from COVID-19,' Stephane Bancel, Moderna's CEO, said in a statement Saturday. The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus. That's the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax. Those restrictions are a departure from how the US has handled COVID-19 vaccines until now, reflecting scepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials. Moderna's existing vaccine doesn't face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall. The news came just days after the Trump administration cancelled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results. STORY CONTINUES BELOW THIS AD
Mint
9 hours ago
- Mint
Bodor Laser's Global Troubles Mount: U.S. Lawsuit, FDA Recall, and Indian Customs Action Raise Red Flags Over Safety
May 2025 |— Bodor Laser, a laser cutting machine manufacturer that once touted itself as a global leader, is now grappling with mounting regulatory and legal scrutiny across two of the world's largest industrial markets: the United States and India. In the U.S., Bodor is facing a multi-million-dollar wrongful death lawsuit filed in Nevada following the fatal crushing of a 38-year-old worker, Jose Luis Ortiz Rojas, at a manufacturing facility in Las Vegas. The incident involved a Bodor P3015 laser cutting machine, which allegedly failed to detect Ortiz's presence after he opened the side door. Despite the company's promotional claims of 'intelligent visual collision avoidance,' the lawsuit asserts that the machine's safety system was either disabled or nonfunctional at the time of the accident. The plaintiff's family further accuses Bodor of fraudulent marketing practices, arguing that the company misled customers via exaggerated safety claims on its website and in product videos. The civil case has ignited serious concerns among U.S. regulators and industrial buyers, with product liability, gross negligence, and deceptive trade practices forming the core of the legal complaint. Adding regulatory weight to the controversy, the U.S. Food and Drug Administration (FDA) recently issued a Class II recall affecting 269 units of Bodor's P and C Series laser cutting machines produced between 2018 and 2024. The recall notice cited the absence of mandatory interlock systems, lack of presence detection, and improper certification labeling. In 2024, the FDA issued a formal Import Alert, subjecting further shipments to heightened scrutiny or outright refusal of entry into the U.S. market. Bodor has since announced corrective measures, including hardware retrofits and on-site inspections, but the damage to its reputation appears significant. Several U.S.-based metal fabricators are reportedly reassessing their Bodor installations in light of the recall. While Bodor's challenges in the U.S. stem from product safety and regulatory labeling, the company's India operations are now embroiled in a separate, high-stakes customs dispute. In October 2024, Chennai Customs seized three consignments of laser machines imported by Bodor Laser India Pvt. Ltd., citing false declaration of origin. The shipments were listed as 'Made in Thailand,' but inspections revealed substantial Chinese-origin components and packaging — a potential attempt to bypass India's anti-dumping duties on Chinese goods. The seized shipments, valued at ₹ 37.7 million, have not been released. Indian authorities have demanded a provisional bond of ₹ 152 million (roughly USD 1.8 million) to cover potential penalties and duties. The matter is being investigated under Sections 110 and 114A of the Customs Act, and criminal prosecution is reportedly under consideration. When seen together, the U.S. safety violations, FDA recall, and Indian customs seizure suggest a troubling pattern of systemic noncompliance across multiple jurisdictions. Bodor's marketing claims, safety engineering, and trade conduct are all under the microscope. As both developed and emerging markets tighten oversight on imported industrial equipment, Bodor Laser's challenges serve as a high-profile warning to global exporters: regulatory diligence is not optional—it's the price of long-term market access.
